Lack of Major Involvement of Common CYP2C Gene Polymorphisms in the Risk of Developing Cross-Hypersensitivity to NSAIDs

• Príomhchruthaitheoirí: Yolanda Macías (Údar), Jesús M. García-Menaya (Údar), Manuel Martí (Údar), Concepción Cordobés (Údar), Raquel Jurado-Escobar (Údar), José A. Cornejo-García (Údar), María J. Torres (Údar), Natalia Blanca-López (Údar), Gabriela Canto (Údar), Miguel Blanca (Údar), José J. Laguna (Údar), Joan Bartra (Údar), Ana Rosado (Údar), Javier Fernández (Údar), Elena García-Martín (Údar), José A. G. Agúndez (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Frontiers Media S.A., 2021-09-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Cross-hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) is a relatively common, non-allergic, adverse drug event triggered by two or more chemically unrelated NSAIDs. Current evidence point to COX-1 inhibition as one of the main factors in its etiopathogenesis. Evidence also suggest...